Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclic AMP-specific phosphodiesterase 4 (PDE4) is an enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP) into inactive adenosine monophosphate (AMP), thereby regulating cellular concentrations of this critical second messenger. The enzyme plays a central role in controlling both the magnitude and duration of cAMP-mediated signaling within cells. There are four genes encoding multiple isoforms within the PDE4 family, each with distinct regulatory sequences allowing tissue-, cell-, or even subcellular-compartment–specific expression patterns. These isoforms underpin compartmentalized cAMP signaling crucial for diverse physiological processes including immune response modulation, neuronal plasticity, inflammation control, cardiovascular function regulation, and more. Pharmacological inhibition of PDE4 leads to increased intracellular cAMP levels which exerts anti-inflammatory effects by suppressing pro-inflammatory cytokines while enhancing anti-inflammatory mediators. This has made PDE4 a validated therapeutic target in diseases such as chronic obstructive pulmonary disease (COPD), psoriasis/psoriatic arthritis, atopic dermatitis, certain psychiatric conditions like depression or schizophrenia—and it is under investigation for substance dependence therapies. Despite their promise as drug targets across multiple indications—including inflammatory diseases and CNS disorders—the clinical development of broad-spectrum PDE4 inhibitors has been limited by dose-limiting gastrointestinal side effects such as nausea/emesis. These adverse events are believed to be related primarily to inhibition of specific subtypes like PDE4D, especially outside intended target tissues.
Inhibition of PDE4 increases intracellular cAMP levels by blocking its degradation, leading to anti-inflammatory and neuroprotective effects as well as modulation of immune cell function and neurotransmission.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic AMP-specific phosphodiesterase 4 (PDE4).